Bausch Health Cos Inc. (BHC) – What Are Brokerages Thinking About This Stock?

Posted by Brenda Bartman on Nov 12th, 2026

Bausch Health Cos Inc. (NYSE:BHC – Get Free Report) has been assigned a consensus recommendation of “Reduce” from the seven brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a hold recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $8.75.

BHC has been the subject of several analyst reports. Zacks Research lowered Bausch Health Cos from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 5th. Wall Street Zen raised shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 1st. Royal Bank Of Canada lifted their target price on shares of Bausch Health Cos from $9.00 to $10.00 and gave the company a “sector perform” rating in a research note on Thursday, October 29th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Bausch Health Cos in a report on Thursday, October 29th. Finally, Barclays increased their price target on Bausch Health Cos from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Wednesday.

Check Out Our Latest Analysis on BHC

Bausch Health Cos Trading Up 0.7%

BHC opened at $8.35 on Friday. The company has a market cap of $3.12 billion, a price-to-earnings ratio of -3.64 and a beta of 0.30. The company’s 50 day moving average is $6.51 and its 200 day moving average is $5.77. Bausch Health Cos has a 12-month low of $4.33 and a 12-month high of $9.04.

Bausch Health Cos (NYSE:BHC – Get Free Report) last announced its earnings results on Wednesday, October 28th. The company reported $1.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.52. Bausch Health Cos had a negative net margin of 7.57% and a negative return on equity of 401.73%. The company had revenue of $2.90 billion during the quarter, compared to analyst estimates of $2.72 billion. As a group, analysts predict that Bausch Health Cos will post 4.53 EPS for the current fiscal year.

Insider Activity

In other news, insider Aimee Lenar sold 36,827 shares of Bausch Health Cos stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $7.03, for a total transaction of $258,893.81. Following the sale, the insider owned 334,853 shares in the company, valued at $2,354,016.59. This trade represents a 9.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Bausch Health Cos

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Private Advisor Group LLC purchased a new stake in Bausch Health Cos during the third quarter valued at $104,000. Cibc World Market Inc. grew its stake in shares of Bausch Health Cos by 335.3% in the 3rd quarter. Cibc World Market Inc. now owns 641,095 shares of the company’s stock worth $3,735,000 after buying an additional 493,828 shares in the last quarter. Virtus Advisers LLC purchased a new position in shares of Bausch Health Cos in the 3rd quarter worth $238,000. Ritholtz Wealth Management increased its holdings in shares of Bausch Health Cos by 6.1% in the 3rd quarter. Ritholtz Wealth Management now owns 192,524 shares of the company’s stock worth $1,122,000 after buying an additional 10,984 shares during the last quarter. Finally, Lido Advisors LLC increased its holdings in shares of Bausch Health Cos by 421.6% in the 3rd quarter. Lido Advisors LLC now owns 372,508 shares of the company’s stock worth $2,172,000 after buying an additional 301,098 shares during the last quarter. Institutional investors own 78.65% of the company’s stock.

Bausch Health Cos Company Profile

(Get Free Report)

Bausch Health Companies Inc. is a global specialty pharmaceutical and medical products company headquartered in Laval, Quebec. It develops, manufactures and markets prescription medicines, over-the-counter products and medical devices, with businesses spanning eye health, gastroenterology, dermatology, neurology and aesthetics. Its portfolio includes Salix products for gastrointestinal conditions, Ortho Dermatologics treatments for skin conditions and Solta Medical aesthetic devices. Bausch Health also retains a controlling ownership interest in Bausch + Lomb, a publicly traded eye-health company whose products include contact lenses, lens care products, pharmaceuticals and surgical devices.